Pavmed Inc. · NASDAQ:PAVM
Pavmed — Investor Presentation (April 2021)
50 slides from Pavmed's investor presentation, Apr 19, 2021
Slide 1: Corporate Overview
XK PAVmed aa eedhar Corporate Overview LISHAN AKLOG, MD Chairman & CEO April 15, 2021 Nasdaq: PAVM, PAVMZ
Slide 2: Disclaimers
Disclaimers This presentation contains certain forward-looking statements that involve risks and uncertainties. * Actual results and events may differ significantly from results and events discussed in forward-looking statements. * Factors that might cause or contribute to such differences include,
Slide 3: Innovating at the speed of life
XK PAVmed __ nasdaq: PAVM INNOVATING AT THE SPEED OF LIFE, Innovating at the speed of life” Transformative medical technologies creating a new standard of care to improve patients’ lives Product Portfolio Diversified across range of clinical conditions Internal and in-licensed/acquired innovations M
Slide 4: Operating Subsidiary: Lucid Diagnostics
XK PAVmed __ nasdaq: PAVM INNOVATING AT THE SPEED OF LIFE, Innovating at the speed of life” Transformative medical technologies creating a new standard of care to improve patients’ lives Operating Subsidiary e (b) Lu Cl 0 Early Precancer Detection to " ; Prevent Esophageal Cancer Deaths diagnostics
Slide 5: Cash & Capitalization
XK PAVmed __ nasdaq: PAVM INNOVATING AT THE SPEED OF LIFE, Innovating at the speed of life” Transformative medical technologies creating a new standard of care to improve patients’ lives Cash & Capitalization Cash as of Dec 31, 2020 2021 Gross proceeds of financings & warrant exercises 2021 Pay-off
Slide 6: Diversified Product Portfolio
Diversified Product Portfolio Creating value by meeting unmet medical needs () Lucid GI Health diagnostics EsoGuard EsoCheck EsoCure -ophageal DNA test Gistcalondiotes esophageal ablation device Suite of products to detect and treat precancer in patients with gastroesophageal reflux disease (GERD) t
Slide 7: Commercially Available Products
Commercially Available Products (B) Lucid xx PAVmed Carp EsoGuard EsoCheck esophageal DNA test cell collection device Minimally Invasive Device to Treat Carpal Tunnel Syndrome Wa =p) =, ee ta a) FD YX 510K Cleared
Slide 8: Executive Leadership Team
Executive Leadership Team ry LISHAN AKLOG, MD Chairman & CEO Executive Chairman, Lucid DENNIS MCGRATH President & CFO & Nd ; BRIAN DEGUZMAN, MD SHAUN O’NEIL RICH YAZBECK Chief Medical Officer Chief Commercial Officer Chief Technology Officer ey RANDY BROWN Chief Operating Officer, Lucid Sy DAVID WUR
Slide 9: World-Renowned Expert Advisors
World-Renowned Expert Advisors STANLEY LAPIDUS Strategic Advisor Founder / Former Chairman & CEO, Exact Sciences Inc. (Nasdaq: EXAS) Founder / Former President, Cytc Inc. (Acquired by Hologic Inc.) Renowned diagnostic industry expert on early detection of cancer and precursors ALBERTO GUTIERREZ Regu
Slide 10: Lucid Diagnostics: EsoGuard and EsoCheck
a Fy (5) Lucid SS diagnostics EsoGuard EsoCheck cell collection devi |
Slide 11: Lucid Diagnostics
(b) Lucid diagnostics A Majority-Owned Subsidiary of PAVmed Inc Commercial-stage medical technology company focused on early precancer detection to prevent esophageal cancer First and only commercially available screening tool to prevent esophageal cancer FDA Breakthrough Device designation 13 milli
Slide 12: GI Early Detection & Treatment Comparables
GI Early Detection & Treatment Comparables (Gb) Lucid diagnostics ESOPHAGEAL CANCER EsoGuard® Esophageal DNA Test EsoCheck® Cell Collection Device é EsoCure™ Esophageal Ablation System $25 Billion Total Addressable Market Opportunity EXACT SCIENCES COLORECTAL CANCER ey Cologuard® Stool DNA Test Nasd
Slide 13: Translational Research Origins
Translational Research Origins cas Westen RESERVE cas Westen UNIVERSITY _ gor i206 e270 Dr. Markowitz Dr. Chak Dr. Willis Dr. Moinova University Hospitals Cleveland Medical Center TWO NOVEL TECHNOLOGIES DNA Methylation Assay Next-generation sequencing (NGS) 31 sites on two genes = CCNA1 and Vimentin
Slide 14: Esophageal Precancer to Cancer Progression
Esophageal Precancer to Cancer Progression
Slide 15: Early Precancer and Cancer Detection Saves Lives
Early Precancer and Cancer Detection Saves Lives Allows intervention to halt progression to more advanced stages CANCER PROGRESSION SPECTRUM EARLY STAGE PRECANCER Screen Intervene Intervene setoteme CANCER TYPE ESOPHAGEAL BREAST | CERVicAL | COLON | _—~ PROSTATE - 5 Men over 50 years Women Women All
Slide 16: Esophageal Precancer to Cancer Progression
Esophageal Precancer to Cancer Progression PREDISPOSING EARLY STAGE LATE STAGE MALIGNANT CONDITION PRECANCER PRECANCER CANCER NONDYSPLASTIC DYSPLASTIC BARRETT’S BARRETT’S ESOPHAGUS ESOPHAGUS GASTROESOPHAGEAL REFLUX DISEASE ESOPHAGEAL ADENOCARCINOMA ( ; Esophagus ah WY ips NDBE LGD/HGD L od ' ‘Vz N P
Slide 17: Gastroesophageal Reflux Disease (GERD)
Gastroesophageal Reflux Disease (GERD) Commonly known as chronic “heartburn” or acid reflux Symptomatic or asymptomatic Reflux of stomach acid and fluid into the lower esophagus Esophagus NORMAL Sphincter closed | Sphincter open | | “allowing reflux US Adults with Weekly GERD Annual US PPI Sales WEE
Slide 18: Esophageal Adenocarcinoma (EAC)
Esophageal Adenocarcinoma (EAC) Fastest growing rate of all FP Increased EAC Arosa —— cancers 500% Incidence Over Survival After PERNT US EAC Deaths Third most lethal cancer wy Past 40 Years EAC Diagnosis , 9 0; - ” <10% have precancer 700% Change in Age-Adjusted Cancer Incidence Change in Age-Adjus
Slide 19: Precancer Screening is Missing Link to Prevent EAC
Precancer Screening is Missing Link to Prevent EAC Other cancer death rates have fallen 40-50% due to widespread screening Only missing element for precancer detection to prevent EAC is widespread screening tool Precancer screening to prevent EAC At-Risk Resulittien Men > 50 with 1 more RF VY Precan
Slide 20: EAC Precancer Screening to Prevent EAC
EAC Precancer Screening to Prevent EAC Major unmet clinical need Necessary to prevent EAC deaths through early precancer detection ~13 million high-risk GERD patients already recommended for precancer screening by professional society guidelines : Tragic Missed Opportunity To Detect and EAC Is Highl
Slide 21: The EAC Precancer Screening Imperative - EsoGuard + EsoCheck
The EAC Precancer Screening Imperative - EsoGuard + EsoCheck First and only commercially available alternative to endoscopy suitable for widespread EAC precancer screening ES OCU ARD UPPER GI CYTOSRONGE TRANSNASAL CAPSULE Peocanen ENDOSCOPY as ENDOSCOPY ENDOSCOPY "eo OO » @ 3 Non-invasive Yes No Yes
Slide 22: Lucid's EsoGuard vs Exact Sciences' Cologuard
Lucid’s EsoGuard vs Exact Sciences’ ColoGuard EsoGuard’s path to widespread EAC precancer screening similar to ColoGuard’s path to widespread Colon Cancer screening, with certain Jower hurdles EXACT SCIENCES Founded and led by Lucid Strategic Advisor Stanley Lapidus ColoGuard FDA cleared in 2014 aft
Slide 23: The EsoCheck Esophageal Cell Sampling Procedure
The EsoCheck Esophageal Cell Sampling Procedure First and only commercial targeted & protected esophageal cell collection device Proprietary textured balloon ridges swab esophageal cells onto balloon surface ‘510K Cleared rigid plastic capsule & EsoCheck BA anew cell collection device a“ a 5 Nn = .
Slide 24: EsoCheck Procedure Steps
EsoCheck Procedure Steps =F P Inflate & Engage Balloon Collect & Protect Cells Retrieve Device Preserve & Send 24
Slide 25: Slide 25
Slide 26: The EsoGuard Laboratory Developed Test (LDT)
The EsoGuard Laboratory Developed Test (LDT) First & only commercial molecular diagnostic test to detect esophageal precancer & cancer Seamle esophageal DNA test EsoGuard @ «x researched) ects " Specimen Kit f Clinician collects esophageal cell sample using EsoCheck ResearchDx performs CLIA = Clinic
Slide 27: EsoGuard Commercial Opportunity & Strategy
EsoGuard Commercial Opportunity & Strategy
Slide 28: EsoGuard Commercial Opportunity
EsoGuard Commercial Opportunity ~13—- ) ~$25 Million » 4 AEST —_ Billion U.S. Male GERD patients CMS Total Immediately recommended for precancer Payment Addressable screening by professional U.S. Market society guidelines _ 1%) $250 Million LONG-TERM EXPANDED MARKET OPPORTUNITIES U.S Female GERD Pat
Slide 29: Multichannel Commercial Strategy
Multichannel Commercial Strategy THE GERD-BE FUNNEL (b) Lucid diagnostics RS Diagnose and treat crs esophageal disease FOREGUT SURGEONS
Slide 30: EsoGuard GI Commercial Channel
EsoGuard GI Commercial Channel Over EsoGuard Estimated 90% Gross Margin at Volume Variable Independent . Ww Sales Rep Cost 25% . Current Target Op tenen 7 BB vid atiantic Employed Regional 8-10 Bi central — National Sales Training Sales Managers TE Texas — strategic Accounts Manager * BE Mid west \
Slide 31: Multichannel Commercial Strategy
Multichannel Commercial Strategy THE GERD-BE FUNNEL a . % [ UCI re —Directto Pepi Channel _ pep Manage most INTERNAL GERD patients Ue diagnostics MEDICINE <Q Diagnose and treat esophageal disease GIs & FOREGUT SURGEONS
Slide 32: Multichannel Commercial Strategy
Multichannel Commercial Strategy THE GERD-BE FUNNEL e PANENTSTS Understand chronic FAMILIES heartburn & cancer a e ee (b) Lu Cl re V_—____aa PCP & Manage most INTERNAL ; diagnostics MEDICINE GERD patients Up <Q Diagnose and treat esophageal disease GIs & FOREGUT SURGEONS
Slide 33: EsoGuard Direct to Consumer Commercial Channel
EsoGuard Direct to Consumer Commercial Channel ee TELEMEDICINE COMPANY Rerennep ‘200roopmec® = Cunical “DTC” EsoGuard.com Evaluation Giusy Telemedicine MD Check your food |tube. EsoGuard
Slide 34: EsoGuard Direct to Consumer Commercial Channel
EsoGuard Direct to Consumer Commercial Channel ee TELEMEDICINE COMPANY SELF- ———______> ini REFERRED 1-800-FOODTUBE Clinical “DTC” EsoGuard.com Evaluation CENT Telemedicine MD Check your nonin food |tube. e (G) Lucid EsoGuard diagnostics EsoCheck Procedure Lucid NP
Slide 35: EsoGuard Direct to Consumer Commercial Channel
EsoGuard Direct to Consumer Commercial Channel ee TELEMEDICINE COMPANY Rerennep ‘200roopmec® = Clinical “DTC” EsoGuard.com Evaluation Giusy Telemedicine MD Resea rch) Check your Fsootard mA PacificDx food |tube. EsoGuard Assay (G) Lucid diagnostics EsoGuard EsoCheck Procedure Lucid NP
Slide 36: EsoGuard Direct to Consumer Commercial Channel
EsoGuard Direct to Consumer Commercial Channel ee TELEMEDICINE COMPANY pecan 1-800-FOODTUBE Clinical “DTC” EsoGuard.com Evaluation EsoGuard Result CAnENT, Telemedicine MD Researc hOX)) Check your Fsootard mA PacificDx food |tube. EsoGuard Assay e (G) Lucid EsoGuard diagnostics EsoCheck Procedure Luc
Slide 37: EsoGuard Direct to Consumer Commercial Channel
EsoGuard Direct to Consumer Commercial Channel EO OMPANY. E GI Referral if EsoGuard+ § Ss se Gr’s & en 1-800-FOODTUBE Clinical SURGEONS “DTC” EsoGuard.com Evaluation Ese Guard Result CAnENT, Telemedicine MD Researc hOX)) Check your Fsootard mA PacificDx food |tube. EsoGuard Assay e (G) Lucid EsoGuar
Slide 38: Lucid Project Phoenix
Lucid Project Phoenix ESOGUARD TEST CENTERS Operated by Lucid EsoCheck performed by Lucid NP el DIRECT-TO- CONSUMER (DTC) MARKETING food |tube. Billboards TV/Radio . EsoGuard Digital 38
Slide 39: Lucid Project Phoenix
Lucid Project Phoenix PHASE 1 ESOGUARD TEST CENTERS Operated by Lucid EsoCheck performed by Lucid NP DIRECT-TO- CONSUMER (DTC) Check your MARKETING food |tube. Billboards TV/Radio Digital 39
Slide 40: Lucid Project Phoenix
Lucid Project Phoenix ESOGUARD TEST CENTERS Operated by Lucid EsoCheck performed by Lucid NP DIRECT-TO- CONSUMER (DTC) Check your MARKETING food |tube. Billboards TV/Radio Digital PHASE 2 40
Slide 41: EsoGuard-EsoCheck Clinical Trials Overview
EsoGuard-EsoCheck Clinical Trials Overview Completed Pilot CASE WESTERN RESERVE S}UNIVERSITY _ esrigas Case/Control 408 Patients EsoGuard vs EGD EsoGuard over 90% Sensitivity & Specificity at detecting precancer or EAC Same EsoGuard results with EsoCheck vs. EGD Brushing Samples Identifying DNA meth
Slide 42: Lucid Growth Strategy
Lucid Growth Strategy COMMERCIAL EXPANSION Expand full-time sales team Nationwide EsoGuard Testing Centers Nationwide DTC marketing GROWTH CAPITAL Spin-off Lucid as separate public company CLINICAL TRIAL EXPANSION Expand clinical evidence to support guidelines Expand BE-1 to be powered to detect dys
Slide 43: CarpX
Carpx’ Minimally Invasive Device to Treat Carpal Tunnel Syndrome 43
Slide 44: Carpal Tunnel Syndrome
Carpal Tunnel Syndrome Median nerve entrapped by wrist ligament scarred by repetitive motion injury #1 workman’s comp injury 600,000 undergo traditional surgery annually Up to 1.5 million “silent sufferers” defer surgery Traditional surgery is invasive 3-4 months recovery, sometimes longer
Slide 45: Precision Bipolar RF Electrosurgical Cutting Tool
Precision Bipolar RF Electrosurgical Cutting Tool Benefits of minimally invasive procedure with the therapeutic results of open surgery Balloon creates anatomic separation Radiofrequency (RF) cutting electrodes mimic traditional surgical cutting blades Very short burst of RF energy _— precisely cuts
Slide 46: CarpX Procedure
CarpX pfocedure “d y 7 a }
Slide 47: CarpX Regulatory History and Commercial Status
CarpX Regulatory History * December 2019: successful first-in-human FDA Clinical safety study * Short learning curve, procedures times same or less than traditional open surgery ¢ April 2020: FDA 510(k) Marketing Clearance Commercial Status * December 2020: First U.S. commercial CarpX procedure perf
Slide 48: Slide 48
Slide 49: Diversified Product Portfolio
Diversified Product Portfolio Creating value by meeting unmet medical needs GI Health EsoCure esophageal ablation device EsoGuard ;ophageal DNA test EsoCheck cell collection device Suite of products to detect and treat precancer in patients with gastroesophageal reflux disease (GERD) to prevent esop
Slide 50: Thank You!
Thank You! CONTACT: Mike Havrilla Director of Investor Relations (814) 241-4138 JMH@PAVmed.com www.pavmed.com Nasdaq: PAVM, PAVMZ SX PAVmed